Mayo Clinic January 14, 2025
John Halamka

Mayo Clinic’s Tapestry Study has demonstrated that next generation genetic analysis can have a significant impact on patient care.

By John Halamka, M.D., President, Mayo Clinic Platform and Paul Cerrato, MA, senior research analyst and communications specialist, Mayo Clinic Platform

On April 14, 2003, the world learned that the Human Genome Project had been completed. As the National Institutes of Health pointed out, it was one of the greatest scientific accomplishments in history and the first completed sequence of the human genome, the DNA that determines not only the color of our eyes, but our susceptibility to many diseases. Unfortunately, many clinicians were disappointed when they realized the data didn’t have an immediate effect on routine patient care. Why...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Clinical Trials, Health System / Hospital, Pharma / Biotech, Precision Medicine, Provider, Trends
Detecting Cancer Before Symptoms? Multicancer Early Detection Leads the Way
“Precision Med Has Evolved as Badly As I Expected” And Other Takeaways From Former FDA Commissioner At PMWC
Advancing Cancer Care: The Role of Radiopharmaceuticals in Precision Medicine
Exploring Precision Medicine and PGx: Sara Rogers, PharmD, Previews Precision Medicine World Conference 2025
India targets to sequence 10 million genomes

Share This Article